A modified regimen of rituximab in pemphigus: A retrospective study
Introduction: Rituximab is a chimeric monoclonal antibody targeted against CD20 T-cells. It acts by the destruction of autoreactive B-cells. It is a common biologic agent widely used for the treatment of B-cell lymphoma, lymphoproliferative disorders, and inflammatory conditions that are refractory...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2020-01-01
|
| Series: | Clinical Dermatology Review |
| Subjects: | |
| Online Access: | http://www.cdriadvlkn.org/article.asp?issn=2542-551X;year=2020;volume=4;issue=1;spage=36;epage=41;aulast=Vaidya |